Salvage external beam radiotherapy for prostate cancer after radical prostatectomy

ONCOLOGY

Volumn 24, Issue 8, 2010, Pages

  Raldow, Ann ^a   Hamstra, Daniel A ^b   Kim, Sung ^c   Yu, James B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE;

BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PATIENT SELECTION; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REVIEW;

EID: 77958052638     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Jemal A, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009.
2. Underwood W, 3rd, et al: Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 103:538-545, 2005.
3. Bill-Axelson A, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977-1984, 2005.
4. Cooperberg MR, et al: The contemporary management of prostate cancer in the United States: Lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171: 1393-1401, 2004.
5. Klein EA, et al: Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 179: 2212-2216; discussion 2216-2217, 2008.
6. Swanson GP, Riggs M, Hermans M: Pathologic findings at radical prostatectomy: Risk factors for failure and death. Urol Oncol 25:110-114, 2007. (Pubitemid 46349747)
7. Vis AN, Schroder FH, van der Kwast TH: The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 50: 258-265, 2006.
8. Dahl DM, et al: Pathologic outcome of laparoscopic and open radical prostatectomy. Urology 68:1253-1256, 2006. (Pubitemid 44880340)
9. Katz MS, et al: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21:483-489, 2003.
10. Roehl KA, et al: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172: 910-914, 2004.
11. Freedland SJ, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005.
12. Bolla M, et al: Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366:572-578, 2005. (Pubitemid 41140332)
13. Thompson IM, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol 181:956-962, 2009.
14. Wiegel T, et al: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924-2930, 2009.
15. Pound CR, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999.
16. Trapasso JG, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152(5 pt 2):1821-1825, 1994.
17. Zincke H, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.J Urol 152(5 pt 2):1850-1857, 1994.
18. Stamey TA, et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987.
19. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997.
20. Lange PH, et al: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141:873-879, 1989. (Pubitemid 19108662)
21. Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 163:1632-1642, 2000. (Pubitemid 30366704)
22. Cookson MS, et al: Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177: 540-545, 2007.
23. Freedland SJ, et al: Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61:365-369, 2003.
24. Scher HI, et al: Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate- Specific Antigen Working Group. J Clin Oncol 22:537-556, 2004.
25. Stephenson AJ, et al: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25:2035-2041, 2007.
26. Parker C, et al: Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 99:1376-1379, 2007.
27. King CR, Kapp DS: Radiotherapy after prostatectomy: Is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71:346-350, 2008.
28. Feng M, et al: Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 68:1417-1423, 2007.
29. Trock BJ, et al: Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299: 2760-2769, 2008.
30. Kuban D, Pagliaro L: Salvage radiotherapy or observation after radical prostatectomy in the PSA era. Am J Hem Onc 8:136-138, 2009.
31. Lee AK, DAmico AV: Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23:8192-8197, 2005.
32. Losa A, et al: Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy. Urology 62:1068-1072, 2003. (Pubitemid 37510093)
33. Niehoff P, et al: Feasibility and preliminary outcome of salvage combined HDR brachytherapy and external beam radiotherapy (EBRT) for local recurrences after radical prostatectomy. Brachytherapy 4:141-145, 2005.
34. Poortmans P, et al: Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 84:121-127, 2007.
35. Michalski JM, et al: Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 76:361-368, 2010.
36. Wiltshire KL, et al: Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys 69:1090-1099, 2007.
37. Miralbell R, et al: Endorectal MRI assessment of local relapse after surgery for prostate cancer: A model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 67:356-361, 2007. (Pubitemid 46108320)
38. Silverman JM, Krebs TL: MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 168:379-385, 1997.
39. Sella T, et al: Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology 231:379-385, 2004. (Pubitemid 38552892)
40. Wang K, et al: The uncertainties in target localization for prostate and prostate-bed radiotherapy with Calypso 4D. Int J Radiat Oncol Biol Phys 75:S594, 2009.
41. Schiffner DC, et al: Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys 67:610-619, 2007.
42. Nath SK, Sandhu AP, Rose BS, et al: Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009 Nov 23 [e-pub ahead of print].
43. Anscher MS, Clough R, Dodge R: Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 48:369-375, 2000.
44. Valicenti RK, et al: Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 42:501-506, 1998.
45. Macdonald OK, et al: Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol 170:1833-1837, 2003.
46. Pollack A, et al: Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105, 2002. (Pubitemid 34787842)
47. Zietman AL, et al: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294:1233-1239, 2005.
48. Kupelian P, et al: Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61:415-419, 2005.
49. King CR, Spiotto MT: Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 71:23-27, 2008.
50. Cox JD, et al: Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17:1155, 1999.
51. Wong GW, et al: Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 70:449-455, 2008.
52. Abramowitz MC, Pollack A: Postprostatectomy radiation therapy for prostate cancer. Semin Radiat Oncol 18:15-22, 2008.
53. Bolla M, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phaseIII randomised trial. Lancet 360:103-106, 2002.
54. DAmico AV, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004.
55. Lawton CA, et al: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49:937-946, 2001.
56. Moinpour CM, et al: Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 26:112-120, 2008.
57. Pearse M, et al: Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate specific antigen relapse or local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys 72:792-798, 2008.
58. Peterson JL, et al: Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol 93:203-206, 2009.
59. Pinkawa M, et al: Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancera prospective analysis. Radiother Oncol 88:135-139, 2008. (Pubitemid 351888892)
60. Sanda MG, et al: Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 358:1250-1261, 2008.
61. Hedestig O, et al: Living after radical prostatectomy for localized prostate cancer: A qualitative analysis of patient narratives. Acta Oncol 44:679-686, 2005. (Pubitemid 41547068)
62. Bokhour BG, et al: Sexuality after treatment for early prostate cancer: Exploring the meanings of erectile dysfunction. J Gen Intern Med 16:649-655, 2001.
63. Katz A: What happened? Sexual consequences of prostate cancer and its treatment. Can Fam Physician 51:977-982, 2005. (Pubitemid 41015516)
64. Miller DC, et al: Long-term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 23:2772-2780, 2005.
65. van der Wielen GJ, Mulhall JP, Incrocci L: Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: A critical review. Radiother Oncol 84:107-113, 2007.
66. Wittmann D, et al: Counseling patients about sexual health when considering postprostatectomy radiation treatment. Int J Impot Res 21:275-284, 2009.
67. Hu JC, et al: The effect of postprostatectomy external beam radiotherapy on quality of life: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor. Cancer 107:281-288, 2006.
68. Formenti SC, et al: Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy. Urology 56:453-458, 2000.
69. Schulman KL, Kohles J: Economic burden of metastatic bone disease in the U.S. Cancer 109:2334-2342, 2007.
70. American Cancer Society: Cancer Facts and Figures 2009. Available at http://www.cancer.org/docroot/ STT/content/STT-1x-Cancer-Facts-- Figures-2009.asp.
71. Zubek VB, Konski A: Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. Mol Diagn Ther 13:31-47, 2009.
72. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16:199-208, 1990.
73. Stephenson AJ, et al: Salvage therapy for locally recurrent prostate cancer after external beam radiotherapy. Curr Treat Options Oncol 5:357-365, 2004.
74. Moreira DM, et al: Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: Results from the SEARCH database. BJU Int 104:1452-1456, 2009.